CALL FOR PAPERS – ASSAY and Drug Development Technologies
Kaylene J. Simpson, PhD
Head, Victorian Center for Functional Genomics
Peter MacCallum Cancer Centre
Myles Fennell, PhD
Memorial Sloan Kettering Cancer Center
New York, USA
Deadline for manuscript submission: May 17, 2017
The Society of Biomolecular Imaging and Informatics (SBI2) is an international community of leaders, scientists, and students promoting technological advancement, discovery, and education to quantitatively interrogate biological models to provide high context information at the cellular level.
In collaboration with the organizers of SBI2, the Editors of ASSAY and Drug Discovery Technologies will dedicate this special issue specifically to biomolecular imaging and informatics research featured at the 2017 SBI2 Annual Conference held at the San Diego Convention Center, September 13–15 2017. This issue will be published to coincide with the annual meeting and will be distributed to all meeting attendees.
All SBI2 members and meeting attendees are cordially invited to submit their papers for consideration from now through May 15, 2016. Accepted papers will be showcased at the 2017 SBI2 meeting.
We are seeking high-quality review articles and original articles on the following topics related to the influence of SBI2 Research:
- Image based HTS
- Phenotypic profiling in chemical biology and drug discovery
- High content analytics
- Innovations — 3D, co-cultures and stem cell systems
Manuscripts should be approximately 3,000 words in length with a 300 word maximum for abstracts. All additional information for submission can be found in our Instructions for Authors.
ASSAY and Drug Discovery Technologies delivers access to the techniques and tools that enable new advances in early-stage screening, and lead to therapeutic compounds for drug discovery and development. This authoritative, rapidly peer-reviewed journal features original papers, application-oriented technology reviews, and reports in methodology and technology application.
Advantages of publishing in ASSAY and Drug Development Technologies include:
- Fast and user-friendly electronic submission
- Rapid, high-quality peer review
- Maximum exposure: accessible in 170 countries worldwide
- Open Access options available
Please address any questions to Kaylene Simpson